 ration return downgrad
neutral balanc risk/reward
messag share impress move past month sinc
bottom low august share seem get credit stabil
oper make progress outstand opioid litig share
trade consensu ebitda roughli premium peer
feel comfort earn expect head
believ current valuat risk/reward share balanc
lower rate neutral buy remov price target
bottom line oper stabil expect valuat
recalibr head investor concern outlook
medic segment well direct on-going
opioid litig upgrad share august view market overli
pessimist number front last four month much clariti
gain confid oper busi segment
cumul impact optum kr contract renew
weigh margin much investor fear medic segment compani
continu make slow steadi oper progress final relat
opioid litig compani made reason progress track toward global
settlement continu believ manag scenario
aforement progress gone unnot investor share risen
nearli low late august vs send valuat lowest
peer group highest continu confid oper
rel consensu expect believ fundament outlook much
balanc addit modestli concern heard much opioid
settlement negoti almost two month sinc negoti parti sat
weekend avert mdl trial outlin base case continu
wide-reach settlement eventu happen manag
scenario would offer outcom alreadi partial discount share
valuat expect
get two-third credit opioid settlement may may happen
news news rememb way back octob
day highly-public opioid mdl trial set begin feder court
cleveland hard believ two month ago seem much longer
may recal frantic negoti weekend prior three distributor agre settl
summit cuyahoga counti success avert go trial monday
octob also encourag three distributor agre upon framework
broader global settlement state attorney gener continu believ
negoti continu increment concern heard
progress toward settlement term framework may suggest
bid/ask dollar amount framework may wider initi anticip
admittedli increment inform passag time
stock perspect believ share get reason credit
settlement may may happen emphas balanc risk/reward
remind term agreed-upon framework would expect
pay year compani felt confid enough negoti begin
accru amount compani industri peer chose
accru respect global settlement amount
remain strong balanc sheet alreadi leverag head
potenti settlement expect gener roughli
put yield right septemb estim balanc
sheet leverag net ebitda overli concern
debt level given healthi cash flow thought worth note given
page analyst certif import disclosur
uncertainti associ on-going opioid litig would also point
lever drug distribut group
pharmaceut busi digest contract repric better expect op
profit still contract compani confer call manag guid
segment oper profit high-singl low-doubl
digit percentag despit cumul effect renew optum
contract guidanc wors investor expect particularli tri
reconcil competitor commentari compani report oper earn
segment stock perspect encourag fact
consensu expect forecast declin oper profit
believ compani could posit perform better long
brand gener price level hold within recent rang posit
near-term stock perspect worth mention segment still significantli
under-perform peer y/i oper profit growth basi fiscal year
medic busi stabil visibl remain limit medic busi
sourc controversi cardin well decad last year
compani suffer numer oper problem busi leav
investor wonder compani cordi patient recoveri acquisit
continu skeptic long-term growth potenti
busi cardin umbrella precipit declin oper profit
compani forecast low double-digit growth segment compani
report significantli better expect oper profit result segment
wake strong result note consensu forecast
growth segment feel confid compani
better handl oper issu posit execut guidanc
provid year said emphas visibl segment
rel low result volatil sinc compani enter busi
continu believ compani best path forward creat sharehold valu
spin divis pleas see previou note topic
regulatori climat could impact drug price inflat level hard get
news daili basi find one articl bipartisan polit ambit
combat exorbit drug price inflat level regulatori crystal ball better
anyon els head elect year expect rhetor continu
accordingli increas volatil obviou say distributor benefit
rapid growth respect specialti busi albeit cardin lesser
extent given role distributor play specialti suppli chain robust inflat
benefici oper profit regul curb price inflat level
could neg impact profit busi
three materi risk downgrad believ oper cardin
good posit rel consensu expect see three potenti
path share grind higher expect first probabl
view see potenti upsid estim believ compani better
visibl today vs laid reason conserv assumpt expect
compani continu make progress track toward global settlement
current valuat outlook balanc could signific downsid
negoti break complet believ compani eventu
make decis separ medic busi cardin portfolio
expect value-cr sharehold reason believ
busi make lot sens oper busi
improv upsw
valuat risk remov pt consist rest
neutral rate stock coverag share current trade
consensu ebitda valuat roughli in-line histor
averag roughli premium two closest peer believ
share reason valu fairli balanc risk/reward hesit assign
multipl higher histor averag eventu opioid settlement go
signific cash flow implic go-forward basi also surpris
premium share award rel comp group despit slower
expect growth suggest balanc risk/reward point
primari risk upsid would favor expect gener brand
price trend anoth risk upsid would potenti monet medic
page analyst certif import disclosur
busi primari risk downsid would less favor expect outcom
opioid litig anoth risk downsid would potenti execut
issu medic busi
page analyst certif import disclosur
issu research report guggenheim secur llc guggenheim secur research analyst whose name appear report
herebi certifi view express report accur reflect research analyst person view subject
secur issuer discuss herein ii part research analyst compens directli indirectli relat specif
recommend view express research analyst
research analyst research associ receiv compens base upon variou factor includ qualiti research investor client
feedback guggenheim secur llc overal revenu includ invest bank revenu
guggenheim secur llc affili expect receiv intend seek compens invest bank servic
inc next month
pleas refer websit company-specif disclosur referenc report http //guggenheimsecur bluematrix com/sellside/
disclosur action disclosur inform also avail complianc madison avenu new york ny
rate price target histori cardin inc
creat bluematrix
buy describ stock expect provid total return price appreci plu yield within period
neutral describ stock expect provid total return price appreci plu yield plu minu within
sell describ stock expect provid total neg return price appreci plu yield within period
nr invest rate price target temporarili suspend suspens complianc applic regul and/or
cs coverag suspend guggenheim secur llc suspend coverag compani
nc cover guggenheim secur llc cover compani
monitor describ stock whose compani fundament financi monitor financi project opinion
invest merit compani provid
review ur follow releas signific news compani rate temporarili place review suffici
inform obtain assess analyst
guggenheim secur llc methodolog assign rate may includ follow market capit matur growth/valu volatil
expect total return next month price target base sever methodolog may includ restrict analys
market risk growth rate revenu stream discount cash flow dcf ebitda ep cash flow cf free cash flow ev/ebitda price-to-earnings pe/growth
price-to-cf p/fcf premium discount /averag group ev/ebitda premium discount /averag group price-to-earnings sum part net asset valu dividend return
return equiti roe next month
price target assign buy- sell-rat stock price target neutral-r stock provid discret analyst
page analyst certif import disclosur
